Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision genome editing biotech developing base and prime editors for rare genetic diseases; improved specificity over first-generation CRISPR competing with Beam Therapeutics and Intellia.
Veda Bio is a biotechnology company developing novel therapeutics for rare genetic diseases and cancer using its proprietary precision genome editing platform — enabling targeted genetic corrections with greater specificity and reduced off-target editing compared to first-generation CRISPR tools. Founded in 2019 and headquartered in Seattle, Washington, Veda Bio was founded by genome editing pioneers and has raised early-stage funding to develop its differentiated editing technology platform.\n\nVeda Bio's platform focuses on delivering precision genetic medicine that can address root causes of genetic diseases rather than managing symptoms. The company's approach aims to improve on first-generation CRISPR-Cas9 by developing base editors and prime editors that can make specific genetic corrections (single letter DNA changes, small insertions or deletions) without introducing double-strand DNA breaks that create higher off-target editing risk. This precision is critical for therapeutic applications where off-target genomic changes could have serious safety consequences.\n\nIn 2025, Veda Bio operates in the competitive genome editing therapeutics space alongside Intellia Therapeutics, Beam Therapeutics (base editing pioneer), Prime Medicine, and CRISPR Therapeutics. The genome editing field experienced a landmark moment in 2023 with the FDA approval of Casgevy (the first CRISPR-based therapy, for sickle cell disease and beta-thalassemia, developed by Vertex and CRISPR Therapeutics) — validating the genome editing therapeutic modality and creating competitive pressure for improved precision editing platforms. Veda Bio's 2025 strategy focuses on advancing lead programs in rare genetic indications through preclinical development toward IND applications, publishing research to establish scientific credibility, and exploring partnerships or licensing with larger biopharmaceuticals for clinical development.
SF AI healthcare administration automating medical coding, billing, and claims for clinics with 30% cost savings and 20% fewer denials; YC S23 $4.5M competing with Waystar for revenue cycle management automation.
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Graphene Ventures, and Orange Collective — providing medical clinics and healthcare providers with autonomous AI agents that handle medical coding, billing, claims submission, denial management, scheduling coordination, and patient payment collection, automating 80%+ of the repetitive administrative tasks that currently consume 30-40% of healthcare provider revenue in overhead costs. Founded in 2023 by Daniyal Afzal, James Oswald, and Kevin Cheng, Decoda's AI agents deliver 30% reduction in coding costs, 20% reduction in claim denials, and claims processing in seconds versus the days that manual coding and submission require.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.